

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

granzyme B (2C5)

RRID:AB_2232723

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-8022, RRID:AB_2232723

Antibody Information

URL: http://antibodyregistry.org/AB_2232723

Proper Citation: Santa Cruz Biotechnology Cat# sc-8022, RRID:AB_2232723

Target Antigen: granzyme B (2C5)

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: ELISA; Flow Cytometry; Western Blot; WB, IP, ELISA; Immunoprecipitation; Other

Antibody Name: granzyme B (2C5)

Description: This monoclonal targets granzyme B (2C5)

Target Organism: rat, mouse, human

Antibody ID: AB_2232723

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-8022

Record Creation Time: 20250819T225647+0000

Record Last Update: 20250820T034753+0000

Ratings and Alerts

No rating or validation information has been found for granzyme B (2C5).

No alerts have been found for granzyme B (2C5).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Stupichev D, et al. (2025) AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma. Cell reports. Medicine, 6(8), 102299.

Kader T, et al. (2024) Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. Cancer discovery.

Miheecheva N, et al. (2022) Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity. Cell reports, 40(7), 111180.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell, 185(9), 1521.

Zhang C, et al. (2020) STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth. Cell metabolism, 31(1), 148.

Jiang L, et al. (2020) Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell, 183(5), 1219.

Byun JK, et al. (2020) Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity. Molecular cell, 80(4), 592.